Is a second course of intravenous immunoglobulin treatment in Guillain-Barré syndrome justifiable?

Is a second course of intravenous immunoglobulin treatment in Guillain-Barré syndrome justifiable?

•Responsiveness to a second course of IVIg treatment may be simply a coincidence.•IVIg may benefit the patient with regard to anti-infection treatment.•Complications or comorbidities should be considered before a second course of treatment.

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of clinical neuroscience 2020-07, Vol.77, p.251-252
Hauptverfasser: Yang, Jingyan, Jia, Rufu
Format: Artikel
Sprache:eng
Schlagworte:
Guillain-Barré syndrome
Intravenous immunoglobulin
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 252
container_issue
container_start_page 251
container_title Journal of clinical neuroscience
container_volume 77
creator Yang, Jingyan
Jia, Rufu
description •Responsiveness to a second course of IVIg treatment may be simply a coincidence.•IVIg may benefit the patient with regard to anti-infection treatment.•Complications or comorbidities should be considered before a second course of treatment.
doi_str_mv 10.1016/j.jocn.2020.04.100
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2398160725</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0967586820305464</els_id><sourcerecordid>2398160725</sourcerecordid><originalsourceid>FETCH-LOGICAL-c330t-400735bc8892425d90cedb560edda7e1b64401195073a219f8aedb3b281310ed3</originalsourceid><addsrcrecordid>eNp9kE1KBDEQhYMoOv5cwIVk6abHStK_IIiKjgOCG12HdLpa0nQnmnQPzJE8hxczw4wuXRVUfe9R7xFyzmDOgOVX3bxz2s45cJhDGnewR2YsEzzheSb2yQyqvEiyMi-PyHEIHQBUqYBDciS4yHlasBnRy0AVDaidbah2kw9IXUuNHb1aoXVToGYYJuvee1dPvbF09KjGAe0YIbqYTN8rY5M75f33Fw1r23g3IO2mMJrWqLrHm1Ny0Ko-4NlunpC3x4fX-6fk-WWxvL99TrQQMCYpQCGyWpdlxVOeNRVobOosB2waVSCr8zQFxqosYoqzqi1VvIual0ywCIkTcrn1_fDuc8IwysEEjfFBizGI5KIqWQ4FzyLKt6j2LgSPrfzwZlB-LRnITbmyk5ty5aZcCWncQRRd7PynesDmT_LbZgSutwDGlCuDXgZt0MYYxqMeZePMf_4_cMyMeA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2398160725</pqid></control><display><type>article</type><title>Is a second course of intravenous immunoglobulin treatment in Guillain-Barré syndrome justifiable?</title><source>Elsevier ScienceDirect Journals</source><creator>Yang, Jingyan ; Jia, Rufu</creator><creatorcontrib>Yang, Jingyan ; Jia, Rufu</creatorcontrib><description>•Responsiveness to a second course of IVIg treatment may be simply a coincidence.•IVIg may benefit the patient with regard to anti-infection treatment.•Complications or comorbidities should be considered before a second course of treatment.</description><identifier>ISSN: 0967-5868</identifier><identifier>EISSN: 1532-2653</identifier><identifier>DOI: 10.1016/j.jocn.2020.04.100</identifier><identifier>PMID: 32362471</identifier><language>eng</language><publisher>Scotland: Elsevier Ltd</publisher><subject>Guillain-Barré syndrome ; Intravenous immunoglobulin</subject><ispartof>Journal of clinical neuroscience, 2020-07, Vol.77, p.251-252</ispartof><rights>2020 Elsevier Ltd</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c330t-400735bc8892425d90cedb560edda7e1b64401195073a219f8aedb3b281310ed3</citedby><cites>FETCH-LOGICAL-c330t-400735bc8892425d90cedb560edda7e1b64401195073a219f8aedb3b281310ed3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0967586820305464$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32362471$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Yang, Jingyan</creatorcontrib><creatorcontrib>Jia, Rufu</creatorcontrib><title>Is a second course of intravenous immunoglobulin treatment in Guillain-Barré syndrome justifiable?</title><title>Journal of clinical neuroscience</title><addtitle>J Clin Neurosci</addtitle><description>•Responsiveness to a second course of IVIg treatment may be simply a coincidence.•IVIg may benefit the patient with regard to anti-infection treatment.•Complications or comorbidities should be considered before a second course of treatment.</description><subject>Guillain-Barré syndrome</subject><subject>Intravenous immunoglobulin</subject><issn>0967-5868</issn><issn>1532-2653</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNp9kE1KBDEQhYMoOv5cwIVk6abHStK_IIiKjgOCG12HdLpa0nQnmnQPzJE8hxczw4wuXRVUfe9R7xFyzmDOgOVX3bxz2s45cJhDGnewR2YsEzzheSb2yQyqvEiyMi-PyHEIHQBUqYBDciS4yHlasBnRy0AVDaidbah2kw9IXUuNHb1aoXVToGYYJuvee1dPvbF09KjGAe0YIbqYTN8rY5M75f33Fw1r23g3IO2mMJrWqLrHm1Ny0Ko-4NlunpC3x4fX-6fk-WWxvL99TrQQMCYpQCGyWpdlxVOeNRVobOosB2waVSCr8zQFxqosYoqzqi1VvIual0ywCIkTcrn1_fDuc8IwysEEjfFBizGI5KIqWQ4FzyLKt6j2LgSPrfzwZlB-LRnITbmyk5ty5aZcCWncQRRd7PynesDmT_LbZgSutwDGlCuDXgZt0MYYxqMeZePMf_4_cMyMeA</recordid><startdate>20200701</startdate><enddate>20200701</enddate><creator>Yang, Jingyan</creator><creator>Jia, Rufu</creator><general>Elsevier Ltd</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20200701</creationdate><title>Is a second course of intravenous immunoglobulin treatment in Guillain-Barré syndrome justifiable?</title><author>Yang, Jingyan ; Jia, Rufu</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c330t-400735bc8892425d90cedb560edda7e1b64401195073a219f8aedb3b281310ed3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Guillain-Barré syndrome</topic><topic>Intravenous immunoglobulin</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yang, Jingyan</creatorcontrib><creatorcontrib>Jia, Rufu</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of clinical neuroscience</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yang, Jingyan</au><au>Jia, Rufu</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Is a second course of intravenous immunoglobulin treatment in Guillain-Barré syndrome justifiable?</atitle><jtitle>Journal of clinical neuroscience</jtitle><addtitle>J Clin Neurosci</addtitle><date>2020-07-01</date><risdate>2020</risdate><volume>77</volume><spage>251</spage><epage>252</epage><pages>251-252</pages><issn>0967-5868</issn><eissn>1532-2653</eissn><abstract>•Responsiveness to a second course of IVIg treatment may be simply a coincidence.•IVIg may benefit the patient with regard to anti-infection treatment.•Complications or comorbidities should be considered before a second course of treatment.</abstract><cop>Scotland</cop><pub>Elsevier Ltd</pub><pmid>32362471</pmid><doi>10.1016/j.jocn.2020.04.100</doi><tpages>2</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0967-5868
ispartof Journal of clinical neuroscience, 2020-07, Vol.77, p.251-252
issn 0967-5868
1532-2653
language eng
recordid cdi_proquest_miscellaneous_2398160725
source Elsevier ScienceDirect Journals
subjects Guillain-Barré syndrome
Intravenous immunoglobulin
title Is a second course of intravenous immunoglobulin treatment in Guillain-Barré syndrome justifiable?
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-09T07%3A01%3A20IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Is%20a%20second%20course%20of%20intravenous%20immunoglobulin%20treatment%20in%20Guillain-Barr%C3%A9%20syndrome%20justifiable?&rft.jtitle=Journal%20of%20clinical%20neuroscience&rft.au=Yang,%20Jingyan&rft.date=2020-07-01&rft.volume=77&rft.spage=251&rft.epage=252&rft.pages=251-252&rft.issn=0967-5868&rft.eissn=1532-2653&rft_id=info:doi/10.1016/j.jocn.2020.04.100&rft_dat=%3Cproquest_cross%3E2398160725%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2398160725&rft_id=info:pmid/32362471&rft_els_id=S0967586820305464&rfr_iscdi=true